Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial
Mikhail Kosiborod(AstraZeneca (Brazil)), Adriaan A. Voors(University Medical Center Groningen), Piotr Ponikowski(Wroclaw Medical University), Mitchell A. Psotka(Alaska Heart and Vascular Institute), Sean P. Collins(Wayne State University), Josep Comín‐Colet(Bellvitge University Hospital), Robert J. Mentz(Duke University), Jasper Tromp(Duke-NUS Medical School), Afshin Salsali(Rutgers, The State University of New Jersey), Christiane E. Angermann(Universitätsklinikum Würzburg), Jan Biegus(Wroclaw Medical University), Jon Blatchford(Boehringer Ingelheim (United Kingdom)), Michael E. Nassif(Saint Luke's Health System), Martina Brueckmann, João Pedro Ferreira(Inserm), John R. Teerlink(University of Glasgow)
Cited by 142
Related Papers
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
|European Journal of Heart Failure|2016|5.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k